Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialJastreboff A, Kaplan L, Frias J, Wu Q, Du Y et alN Engl J Med. 2023 Jun 26. www.doi.org/10.1056/NEJMoa2301972

Global Prevalence of PrediabetesRooney M, Fang M, Ogurstsova K, Ozkan B, Echouffo-Tcheugui EDiabetes Care 2023;46(7):1388–1394DOI: https://doi.org/10.2337/dc22-2376